Janet Pope Janetbirdope
1 week ago
Treatment for #lupus #brain #fog?!
#small #RCT of Memantine a N-methyl-D-aspartate receptor (NDAR) antagonist used in #Alzheimers
SLE-more permeability in #brain #SLE -antiDNA cross reacting w NDAR
#memantine N=19 v #PBO N=25 showed more improvemt
#EULAR2026 @RheumNow POS701 https://t.co/qvHOy9oDS7
Jiha Lee JihaRheum
1 week ago
RD in #IBD: 18.6% of 650 IBD pts affected, most commonly peripheral arthritis and AxSpa. Key finding: 14% of rheumatic manifestations preceded IBD diagnosis. Rheumatologists may see these pts first. GI-rheum collaboration is essential. @RheumNow #EULAR2026 POS0807 https://t.co/028yzOxJ2R
sheila RHEUMarampa
1 week ago
What defines MRI indicative of axSpA?
This systematic lit review show adapting more stringent cutoffs in BME (>=4 SIJ quads, erosion >=3 quads, fat >=5 SIJ quads) & combined BME + structural lesions inc specificity.
Time for updated definitions?
AbsPOS0866 @RheumNow #EULAR2026 https://t.co/gkVbcOAiD3
Bella Mehta bella_mehta
1 week ago
Weight management should be discussed!!
Obesity management will help rheumatic diseases. EULAR guidelines below. No ACR ones exist.
Best evidence in OA and Gout.
#EULAR2026 plenary @RheumNow https://t.co/hBu4YeXZbu
Bella Mehta bella_mehta
1 week ago
Metaflammation !! A new term I learnt at #EULAR2026 plenary. @RheumNow
Inflammation triggered by metabolic abnormalities.
This may be the reason a lot of our inflammatory arthritis patients on GLP1 drugs(other indications) have thier disease activities improving. Emerging data.
Mrinalini Dey DrMiniDey
1 week ago
#OP0239: validating 2025 ASAS-SPARTAN axSpA classification criteria in the SPACE cohort. Revised criteria showed high specificity but lower sensitivity than 2009 criteria, reflecting greater emphasis on imaging & less reliance on clinical features alone. #EULAR2026 @RheumNow
Dr. John Cush RheumNow
1 week ago
Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB. All content is independently chosen and produced by the RheumNow faculty.
EULAR works with the network of national organisations of People with Arthritis/Rheumatism in Europe (PARE) to ensure the voices of people with RMD are heard and have influence – creating powerful alliances that make a real difference. Artificial intelligence is another potential ally in that fight. At the EULAR 2026 Congress in London, work was presented from three PARE initiatives that showcase how digital tools can be used in treatment
Bella Mehta bella_mehta
1 week ago
Why are GLP1 agonists important in rheumatology- plenary at #EULAR2026
Presence on leucocytes- change from pro inflammatory to anti inflammatory casade
Also in fibroblasts in rheumatoid arthritis.
Trials on the way for OA, Gout, as well as IBD. @RheumNow https://t.co/WJ6actAzrv
Bella Mehta bella_mehta
1 week ago
Evidence on diet changing prognosis or incidence of rheumatic diseases is limited. However overall need to encourage health diets. Plenary at #EULAR2026 @RheumNow
Summary below. https://t.co/QC0Li38eh6
Md Yuzaiful Md Yusof Yuz6Yusof
1 week ago
#EULAR2026 OP0228 Is there “something in the air?” Data from US Market Scan: poor quality index was associated with increased risk of #SLE. Although causal inference cannot be deduced, seems an important environmental factor. To check air quality assoc with UV index @RheumNow https://t.co/1FOw7RDA9a
Mrinalini Dey DrMiniDey
1 week ago
#OP0224 at #EULAR2026: Poor air quality may contribute to lupus risk. In a cohort of 8.3 million people, higher AQI exposure and more unhealthy air quality days were associated with increased incident SLE. Adds to evidence linking environmental exposures & autoimmunity. @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof
1 week ago
#EULAR2026 OP0216 With the advances in biologics/cell-based therapies in #SLE, we need to define “severe refractory.” Data-driven analysis from 13 nations suggested: SLEDAI≥6 + PGA>1 + mild-moderate or severe flare (MMSf) + GC≥10 +IS. Need validation study before use @RheumNow https://t.co/K2dMSQUIgB
Dr. John Cush RheumNow
1 week ago
RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.
People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. The 2026 EULAR Congress showcased new data and ideas around various comorbidities and drug safety issues in people with an RMD – highlighting the need for integrated care. Here are five abstracts to consider.
